Radiation-Sensitizing Agents

• 

  Subject Areas on Research

  • 4-Fluorobenzylamine and phenylalanine methyl ester conjugates of 2-nitroimidazole: evaluation as hypoxic cell radiosensitizers. 
  • A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? 
  • A manganese porphyrin superoxide dismutase mimetic enhances tumor radioresponsiveness. 
  • A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. 
  • Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. 
  • Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. 
  • Analyzing cell cycle checkpoints after ionizing radiation. 
  • Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. 
  • Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. 
  • Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. 
  • Bromodeoxyuridine-mediated radiosensitization in human glioma: the effect of concentration, duration, and fluoropyrimidine modulation. 
  • Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis. 
  • Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. 
  • Combined treatment approaches in regionally advanced bladder cancer. 
  • Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. 
  • Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. 
  • Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells. 
  • Effect of molecular characteristics on cellular uptake, subcellular localization, and phototoxicity of Zn(II) N-alkylpyridylporphyrins. 
  • Effects of pentobarbital anesthesia on the energy metabolism of murine tumors studied by in vivo 31P nuclear magnetic resonance spectroscopy. 
  • Effects of the interaction between carbogen and nicotinamide on R3230 Ac tumor blood flow in Fischer 344 rats. 
  • Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. 
  • Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. 
  • Factors influencing hyperthermic enhancement of drug cytotoxicity. 
  • Feasibility of laser targeted photo-occlusion of ocular vessels. 
  • GBM radiosensitizers: dead in the water…or just the beginning? 
  • Halogenated pyrimidine sensitization of low dose rate irradiation in human malignant glioma. 
  • Hypoxia in the thymus: role of oxygen tension in thymocyte survival. 
  • Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. 
  • Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. 
  • Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery. 
  • Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials. 
  • Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. 
  • Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas. 
  • Is hyperbaric oxygen more effective than carbogen/nicotinamide in tumor radiation response? 
  • Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? 
  • L-buthionine-sulfoximine-mediated radiosensitization in experimental interstitial radiotherapy of intracerebral D-54 MG glioma xenografts in athymic mice. 
  • Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. 
  • Management of locally advanced adenocarcinoma of the pancreas. 
  • Mechanism of the Antitumor and Radiosensitizing Effects of a Manganese Porphyrin, MnHex-2-PyP. 
  • Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. 
  • Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors. 
  • Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. 
  • Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. 
  • New applications of gemcitabine and future directions in the management of pancreatic cancer. 
  • New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. 
  • Notch promotes radioresistance of glioma stem cells. 
  • Novel Manganese-Porphyrin Superoxide Dismutase-Mimetic Widens the Therapeutic Margin in a Preclinical Head and Neck Cancer Model. 
  • Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents. 
  • Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2). 
  • Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. 
  • Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. 
  • Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer. 
  • Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. 
  • Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line. 
  • Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. 
  • Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. 
  • Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. 
  • Selective laser-activated lesioning of prelabeled fetal hippocampal grafts by intracellular photolytic chromophore. 
  • Spatiotemporally photoradiation-controlled intratumoral depot for combination of brachytherapy and photodynamic therapy for solid tumor. 
  • Strategies for optimizing the response of cancer and normal tissues to radiation. 
  • The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. 
  • The effect of the perflubron emulsion Oxygent on the calibration characteristics of polarographic oxygen electrodes. 
  • The effects of hyperoxic and hypercarbic gases on tumour blood flow. 
  • The in vitro radiosensitization of human glioblastoma with pentoxifylline. 
  • The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine. 
  • Therapeutic effect of infused Fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside. 
  • Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. 
  • Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. 
  • Tumor cells, but not endothelial cells, mediate eradication of primary sarcomas by stereotactic body radiation therapy. 
  • Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. 
  • Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. 
  • Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. 
  • Utilizing Superoxide Dismutase Mimetics to Enhance Radiation Therapy Response While Protecting Normal Tissues. 
  • Variability in blood flow and pO2 in tumors in response to carbogen breathing. 
  • Whole body hyperthermia and heat-sensitizing drugs: a pilot study in canine lymphoproliferative disease.